Botulinum toxin safe and effective for spasmodic dysphonia treatment: BOISS Study

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2021-02-18 16:45 GMT | Update On 2021-02-19 09:02 GMT

Japan: Botulinum toxin injection into laryngeal muscles is safe and effective for the treatment of spasmodic dysphonia (SD), finds a recent study in the European Journal of Neurology.

Botulinum toxin injection is an accepted standard treatment for SD and this study provides additional data for safety and efficacy of this treatment, note the authors.

SD is a rare form of focal dystonia that occurs in the absence of phonatory organ paralysis or other structural pathology. It is characterized by involuntary intermittent spasms of the intrinsic laryngeal muscles. BT injection has been standard treatment for spasmodic dysphonia. However, only a few high‐quality clinical studies have appeared, and BT is used off‐label in most countries.

Masamitsu Hyodo, Kochi University, Nankoku, Japan, and colleagues performed a multicenter, placebo‐controlled, randomized, double‐blinded, parallel‐group comparison/open‐label clinical trial (the BOtulinum toxin Injection therapy for Spasmodic dySphonia [BOISS], study).

The study aimed at obtaining approval for BT therapy for SD in Japan. This is the first clinical trial based on Good Clinical Practice (GCP) guidelines to be conducted on BT worldwide.

The study enrolled twenty‐four patients (22 with adductor SD and two with abductor SD). The primary end point was the change in the number of aberrant morae (phonemes) at 4 weeks after drug injection.

Key findings of the study include:

In the adductor SD group, the number of aberrant morae at 4 weeks after injection was reduced by 7.0 ± 2.30 (mean ± SE) in the BT group and 0.2 ± 0.46 in the placebo group.
The improvement persisted for 12 weeks following BT injections.
The strain element in GRBAS scale significantly reduced at 2 weeks after BT treatment.
The VHI and VAS scores as subjective parameters also improved. In the abductor SD group, one patient responded to treatment.
Adverse events included breathy hoarseness (77.3%) and aspiration when drinking (40.9%) but were mild and resolved in 4 weeks.

"Botulinum toxin injection was safe and efficacious for the treatment of SD. Based on these results, BT injection therapy was approved as an SD treatment in Japan.," concluded the authors.

The study titled, "Botulinum toxin injection into the intrinsic laryngeal muscles to treat spasmodic dysphonia: A multicenter, placebo‐controlled, randomized, double‐blinded, parallel‐group comparison/open‐label clinical trial," is published in the European Journal of Neurology.

DOI: https://onlinelibrary.wiley.com/doi/10.1111/ene.14714

Article Source : European Journal of Neurology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Botulinum toxin safe and effective for spasmodic dysphonia treatment: BOISS Study

Similar News

Interferon alpha Nasal Spray Reduces COVID-19 Risk in Cancer Patients: Study

Azelastine Nasal Spray May Lower COVID-19 Infection Risk: JAMA

Metals and sulfate in air pollution mixture may contribute most to asthma hospitalizations: Study

Over Half of Indian Patients With Nasal Symptoms Have Allergic Rhinitis: Study Finds

15 Percent of COPD Exacerbation Patients Develop Arrhythmias, Tripling In-Hospital Death Risk: Meta-Analysis

Low Vitamin D Levels Associated with Hearing Loss in Meniere's Disease Patients: Study Finds

Minimal-Equipment Pulmonary Rehab Matches Benefits of Full Gym Setup: JAMA

Tongue-to-Oral Height Ratio: New Ultrasonographic Predictor for Difficult Laryngoscopy